Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Share-based Compensation: 2020-2024

Historic Share-based Compensation for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $14.5 million.

  • ARS Pharmaceuticals' Share-based Compensation rose 58.42% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 64.32%. This contributed to the annual value of $14.5 million for FY2024, which is 57.38% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Share-based Compensation stood at $14.5 million, which was up 57.38% from $9.2 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Share-based Compensation high stood at $14.5 million for FY2024, and its period low was $2.6 million during FY2020.
  • Over the past 3 years, ARS Pharmaceuticals' median Share-based Compensation value was $9.2 million (recorded in 2023), while the average stood at $9.9 million.
  • Data for ARS Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 106.54% (in 2022) over the last 5 years.
  • ARS Pharmaceuticals' Share-based Compensation (Yearly) stood at $2.6 million in 2020, then increased by 7.16% to $2.8 million in 2021, then spiked by 106.54% to $5.8 million in 2022, then surged by 58.05% to $9.2 million in 2023, then spiked by 57.38% to $14.5 million in 2024.